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in Parkinson’s Disease
Synuclein Revisited
Studies of PD that have examined the relatively selective
loss of dopaminergic neurons in the SNc suggest that
the presence of abundant Lewy bodies and dystrophic
neurites (“Lewy neurites”) are strongly associated with
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cal hallmark of this disease, consisting of round eosino-2 Institute for Cell Engineering
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wise composed of similar, aggregated proteins (Forno,
1996). The distribution patterns of these structures strongly
correlate with the severity of PD neurodegeneration. In
Previous reports on Parkinson’s disease indicate that the earliest stages of the disease, Lewy body lesions
genetic mutations in -synuclein result in the aberrant initially develop in the medulla oblongata and lower
accumulation of this protein, causing toxic gain of brainstem, are detectable in the basal proencephalon
function leading to the development of Parkinson’s. during the middle stages of PD, and in the last severe
A recent report on the Iowan kindred, an extended form of the illness may appear in the neocortex (Braak
pedigree with an autosomal dominant form of this dis- et al., 2003). It is worth nothing that while damage to
ease, provides new mechanistic insight into Parkin- the SNc is a hallmark for PD, extensive extranigral pa-
son’s disease by showing that an elevation in wild- thology, including lesions in the coeruleus-subcoeruleus
type -synuclein protein is sufficient to develop the complex and subnuclei of the thalamus and amygdala,
early-onset form of the disorder. This review discusses are also associated with this disorder, indicating that
other cell populations are also eventually susceptible tohow insights gained from these studies of -synuclein
synuclein-induced neurodegeneration. However, not allmay direct future research into Parkinson’s disease.
forms of familial PD contain Lewy bodies; mutations in
parkin result in an early-onset form of the disease that
Introduction is inherited in an autosomal recessive manner (ARJP)
Parkinson’s disease (PD) is the most common neuro- (Dawson and Dawson, 2003). There is a notable absence
degenerative movement disorder, affecting approxi- of Lewy bodies in nearly all cases of ARJP.
mately 1% of the population by age 65 and increasing to The first evidence that mutations in the -synuclein
4%–5% of the population by the age of 85. The classical gene were directly associated with early-onset PD came
symptoms of PD become manifest after the loss of 70%– from linkage analysis studies of the Contursi kindred
90% of dopaminergic neurons in the substantia nigra and in several Greek kindreds. Researchers initially
pars compact (SNc), leading to a severe reduction in identified a point mutation (A53T) at position 209 in
dopamine levels in the striatum (Dawson and Dawson, -synuclein resulting in early-onset PD; following this
2003). Classical symptoms of PD that result from the discovery, another linkage analysis study of a German
family with early-onset PD identified A30P, a secondloss of striatal dopamine include bradykinesia, resting
autosomal dominant mutation (Dawson and Dawson,tremor, cogwheel rigidity, and postural instability. PD is
2003). Transgenic models of -synuclein mutations haverecognized by its clinical symptoms and is ultimately
provided important insights into the role of -synucleindiagnosed in postmortem analysis through the loss of
protein in PD. While mutations in other genes can resultdopaminergic cells and the presence of Lewy bodies in
in functionally impaired or inactive protein products,the SNc. Although PD is sporadic in the majority of
studies of -synuclein point to the surprising conclusionpatients, the familial cases of PD (which comprise less
that the detrimental effects from mutant -synuclein ex-than 10% of all diagnoses) have specific genetic risk
pression result from a gain in function of the protein;factors that greatly increase the likelihood of developing
the loss of -synuclein appears to have minimal effectsthis disease (Giasson and Lee, 2003). Mutations in three
on development. -synuclein knockout mice appeargenes, -synuclein, parkin, and DJ-1, are clearly linked
normal and fertile, and the development of the dopamin-to early-onset PD, while mutations in UCH-L1 (a ubiqui-
ergic system is comparable to wild-type animals (Abelio-tin carboxy-terminal hydrolase) are implicated in PD
vich et al., 2000; Cabin et al., 2002). Complementary(Dawson and Dawson, 2003). Although alterations in
studies of Drosophila and transgenic mouse lines showthese genes are the predominant cause of PD, a recent
that overexpression of both mutant and wild-type formspublication on the Iowan kindred have revealed that
of -synuclein can result in the degeneration of dopa-even moderately elevated levels of wild-type -synuclein
minergic neurons; however, not all -synuclein trans-protein are all that are required to cause this disease
genic mouse models develop dopaminergic deficits(Singleton, 2003). This surprising discovery allows us to
(Maries et al., 2003). In studies of Drosophila, lines over-reconsider the role of genetic mutations in PD.
expressing wild-type or A53T -synuclein develop Lewy
body pathology and have an adult-onset loss of dopa-
minergic neurons. A similar effect has been seen in*Correspondence: petrucelli.leonard@mayo.edu
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al., 1996). While this new report reveals that an elevation
in -synuclein is potentially the sole cause of PD in the
Iowan pedigree, it is important to regard this provocative
finding with caution. The triplicated region containing
-synuclein contains an estimated 17 additional genes,
so one or more of these genes may be responsible for
this disorder. However, the most economical explanation
suggests that -synuclein is the culprit in this disease.
Mechanisms of -Synuclein Toxicity
Given the evidence that both mutant -synuclein and
elevated levels of wild-type protein can cause PD, what
is the mechanism of neurotoxicity? Studies of experi-
mental models and PD brain tissue show that the abnor-
mal polymerization of -synuclein into filaments, which
eventually aggregate to form cytoplasmic Lewy bodies,
can impair the function of neurons, glia, and oligodeno-
drocytes (Giasson and Lee, 2003). Familial PD mutations
Figure 1. -Synuclein Pathological Inclusions in Iowan Kindred are also associated with accelerated fibril formation
(A) Appearance of classical LBs stained with hematoxylin and eosin. (Conway et al., 2000). In certain cases, -synuclein ag-
(B) Immunostained for -synuclein from the medulla. gregates can fill most of the cytoplasm of affected cells,
(C) Lewy neurites from hippocampus.
and therefore inclusions have the potential to directly(D) Glial cytoplasmic inclusions from the temporal white matter also
impair normal cellular trafficking, sensitizing these cellsstained with -synuclein.
to death from other stress.
In experimental models of PD, -synuclein over-
expression can selectively kill dopaminergic neurons.transgenic mice expressing both wild-type and mutant
Several groups have generated different animal modelsforms of -synuclein; these lines develop varying de-
with neuronally directed -synuclein expression. In Dro-grees of pathology and -synuclein-based abnormali-
sophila, this expression demonstrated a regionally de-ties, with impaired performance in locomotor-based be-
pendent neurotoxic effect in a subset of dopaminergichavioral tasks (Maries et al., 2003).
neurons with fibrillar inclusions (Feany and Bender,A report published this week in Science by Singleton
2000). One of the first transgenic mouse models withand colleagues (2003) provides a unique mechanistic
wild-type-synuclein overexpression developed intraneu-insight into the pathogenesis of PD. In the original publi-
ronal inclusions, had a loss of striatal tyrosine hydroxy-cation on the Iowan kindred, PD was presented as an
lase-positive terminals (a marker for dopaminergic neu-autosomal dominant disease with extensive Lewy body
rons), and performed poorly on motor test compared topathology and glial cytoplasmic inclusions (Figure 1;
nontransgenic littermates (Masliah et al., 2000). Subse-
Gwinn-Hardy et al., 2000). In the new publication, the
quent studies using viral vector-mediated delivery of
investigators report that the overexpression of wild-type
-synuclein and mutant variants of this gene have shown
-synuclein, in the absence of other known mutations,
that dopaminergic neurons are considerably more vul-
is all that is required to cause PD in this pedigree. In nerable than nondopaminergic neurons in the substantia
the study of Iowan kindred, sequencing of -synuclein, nigra (Kirik et al., 2002).
using both genomic DNA and cDNA, unexpectedly failed In the past few years, a diverse number of explana-
to identify any mutations in-synuclein; affected individ- tions have emerged that explain how -synuclein can
uals had transcripts of normal length and sequence. A be selectively toxic to dopaminergic neurons. Several
subsequent analysis of the allelic ratios of marker SNPs groups suggest that -synuclein oligomers and protofi-
revealed that PD-affected individuals had a genomic brils are important toxic components in PD. Under in
triplication of the region containing -synuclein, with vitro conditions, wild-type -synuclein has been shown
four fully functional copies of this gene. The 2-fold over- to aggregate, and familial mutations accelerate the ag-
expression of this protein was subsequently confirmed gregation rate of this protein into oligomers and pro-
by analysis of mRNA, showing a concomitant increase tofibrils (Conway et al., 2000). Protofibrillar forms of
in soluble -synuclein protein by Western blot analysis. -synuclein have been reported to transiently permea-
An important implication taken from the Iowan study bilize vesicular membranes, altering the intracellular en-
is that the aberrant metabolism of wild-type synuclein vironment and potentially predisposing these cells to
is likely to be a precipitating cause of dopaminergic cell undergoing apoptosis (Volles and Lansbury, 2003). DA
loss in idiopathic PD cases. This discovery is reminiscent can form adducts in vitro with -synuclein, stabilizing
of observations made in Down’s syndrome, demonstra- potentially toxic -synuclein protofibrils (Conway et al.,
ting that early-onset Alzheimer’s disease (AD) strongly 2001). Another group found that-synuclein toxicity was
correlates with elevated levels of wild-type protein. In enhanced by the generation of reactive oxygen species
Down’s syndrome, there is a substantial elevation in in the presence of DA (Xu et al., 2002). In human mesen-
wild-type amyloid precursor protein (APP) resulting from cephalic dopaminergic neurons, elevated levels of solu-
a triplication of chromosome 21 (containing the APP ble -synuclein resulted in the appearance 54–83 kDa
gene); the increased APP gene dosage found in Down’s -synuclein protein complexes. The pharmacological in-
patients is believed to be responsible for the accelerated hibition of DA production using a tyrosine hydroxylase
inhibitor completely inhibited -synuclein-induced apo-amyloid plaque formation and early-onset AD (Teller et
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Figure 2. Putative Mechanisms of-Synuclein
Neurodegeneration in Familial Parkinson’s
Disease
The presence of Lewy bodies in PD is caused
by a failure to properly dispose of -synuclein.
Point mutations in -synuclein (-synucleinmut)
and the recently described Iowan functional
duplication (-synucleindup) lead to excessive
intracellular accumulation of -synuclein, re-
sulting in spontaneous oligomerization of this
protein. Mutant -synuclein can inhibit pro-
teasomal activity, potentially leading to en-
hanced accumulation; soluble -synuclein
protofibrils and intracellular protein aggre-
gates have been shown to impair the protea-
some. Dopamine may also form stable ad-
ducts with protofibrils, potentially enhancing
this toxicity. Genetic mutations associated
with the UPP pathway, including parkin and
UCH-L1, are associated with familiar PD.
Combined with other cellular stress, this
leads to neuronal loss.
ptosis. The group demonstrated that these soluble com- ance between the tendency of -synuclein to undergo
spontaneous self-aggregation and the ability of cells toplexes sequester 14-3-3, a chaperone with a propensity
to bind -synuclein; as this protein inhibits apoptosis, eliminate this protein before it can reach critical intracel-
lular concentrations; in vitro studies using -synucleinsequestration predisposed dopaminergic neurons to
apoptosis from oxidative DA metabolism. In support of show that this protein undergoes concentration-depen-
dent self-aggregation through a nucleation-dependentthe notion that the soluble forms of-synuclein are toxic,
in vitro expression of mutant-synuclein can predispose mechanism (Conway et al., 2000). Consequently, factors
that decrease the efficiency of protein clearance willneuronal cells to toxicity in the absence of neuronal
inclusions (Petrucelli et al., 2002). tip the balance in favor of protein aggregation and will
promote the development of inclusions (Figure 2). Sev-Proteasomal Dysfunction and Parkinson’s Disease
Although the connection between misfolded protein ag- eral studies suggest that the clearance of -synuclein
is impaired in PD brain. -synuclein can be degradedgregates and disease phenotype is still incomplete in
PD, a substantial body of evidence strongly suggests by the proteasome, and mutant -synuclein is degraded
at a significantly slower rate than wild-type protein inthat impaired clearance of damaged proteins can cause
them to become direct participants in the disease pro- vitro (Bennett et al., 1999). This hypothesis is further
supported by data showing reduced proteasomal activ-cess. Under nonpathological situations, proteins in the
cell can be targeted for disposal by two different sys- ity in the SNc in the PD brain (McNaught et al., 2003).
Furthermore, -synuclein inhibits proteasomal activitytems, either by heat-shock protein chaperones (Hsps)
or by the ubiquitin-proteasomal pathway (UPP); these in a concentration-dependent manner through direct in-
teraction with the 26S proteasome complex (Giassonpathways insure that incorrectly folded proteins are se-
questered and rapidly eliminated from the intracellular and Lee, 2003). Taken together, these findings suggest
that accumulation of -synuclein is enhanced throughenvironment. Hsps bind to misfolded proteins, targeting
them for degradation via both lysosomal and proteaso- impaired proteasomal activity.
The relevance of elevated levels of synuclein in itsmal routes (Bonini, 2002). The UPP is the major, nonlyso-
somal route for degradation of damaged and misfolded various forms (soluble monomeners, oligomers, and fi-
brils) and pathogenic synuclein to neurodegenerationproteins (Hochstrasser, 1996). Proteins destined for
degradation undergo ubiquitinination, a highly ordered has been extensively debated. Both soluble and insolu-
ble kinds of -synuclein have important roles in the pro-process where lysine residues on the target molecule
are tagged with ubiquitin moieties in three-step enzy- gression of PD, although these forms of protein are likely
to have differing downstream effects. Soluble forms ofmatic process (E1–E3). The tagged proteins ultimately
undergo proteolytic degradation through an enzymatic -synuclein can cause neurodegeneration in models of
PD, since cell loss in transgenic fly and mouse lines cancomplex called the 26S proteasome.
In PD, the presence of -synuclein-rich Lewy bodies occur in the absence of Lewy bodies (Maries et al.,
2003). Similarly, soluble mutant -synuclein sensitizesis almost certainly the result of inefficient clearance of
-synuclein. The formation of Lewy bodies is an incom- catecholaminergic neurons to proteasomal inhibition
and can inhibit proteasomal activity in neuronal cell cul-pletely understood process that emerges from the bal-
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ture, predisposing these cells to cell death (Petrucelli models of proteasomal function and transgenic lines
et al., 2002). -synuclein fibrils and Lewy bodies also containing different conformational disease proteins will
contribute to the PD phenotype. In humans, Lewy bodies be especially useful in exploring temporal correlations
and Lewy neurite density correlate with the severity of in PD and other diseases. Finally, the exploration of
neurodegeneration and correlate in another disease factors that modify UPP activity has the potential to
known as Lewy bodies with dementia (Braak et al., 2003; greatly increase our understanding of the relationship
Giasson and Lee, 2003). These inclusion bodies can between protein aggregation and neurodegenerative
potentially inhibit protein turnover, since intracellular ag- disease, and ultimately these findings have the potential
gregates have been reported to directly impair proteaso- to allow us to develop novel therapeutic agents that will
mal degradation (Bence et al., 2001); Bence and col- be able to slow or prevent the progression of PD and
leagues demonstrated that the presence of cytoplasmic other neurodegenerative disorders.
aggregates was directly associated with decreased pro-
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